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Don’t let the devil ride
Oh, don’t you let the devil ride
If you let the devil ride, he’ll wanna drive
Don’t let him ride
Don’t you let him flag you down
Oh, don’t you let him flag you down
If he flags you down, he’ll turn your soul around
Don’t let him ride
Don’t you let him be your boss
Oh, don’t you let him be your boss

†
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Phelps & McNamara, P.C. The views expressed in this article are the views of the
author and do not necessarily represent the views of Hyman, Phelps & McNamara,
P.C. or any of its clients.
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If you let him be your boss, your soul will be lost
Don’t let him ride
Don’t let him drive your car
Oh, don’t you let him drive your car
If you let him drive your car, he’ll surely go too far
Don’t let him drive
I.

INTRODUCTION

These lyrics from an unknown author of the gospel song Don’t
Let the Devil Ride tell the story of the consequences of allowing the
devil to take over one’s life by giving into temptation once too
often; by crossing the proverbial line in the sand. The lyrics also
provide a nice characterization of the Food and Drug Administration’s (FDA or “Agency”) nearly thirty years of responding to
citizen petitions requesting permission to submit an Abbreviated
New Drug Application (ANDA) for a proposed drug product that
deviates in some respect from the brand-name Reference Listed
Drug (RLD) relied on for approval—the so-called “petitioned
ANDA.”
1
Submitted pursuant to section 505(j)(2)(C) of the Federal
2
Food, Drug, and Cosmetic Act (FDC Act), as amended by the Drug
3
Price Competition and Patent Term Restoration Act of 1984,
which is more commonly known as the Hatch-Waxman Act, the
petitioned ANDA was, for several years, a mainstay of the generic
4
drug industry’s drug development paradigm. Although the
popularity of the petitioned ANDA has waned in recent years, it
remains a viable route for many generic drug applicants to obtain
approval of a drug product without having to conduct expensive
and time-consuming clinical studies. However, the continued
success—and reinvigoration—of the petitioned ANDA depends in
large part on the FDA’s ability to promptly review and act on ANDA
suitability petitions within the statutory ninety-day period.
1. Federal Food, Drug, and Cosmetic (FDC) Act § 505(j)(2)(C), 21 U.S.C.
§ 355(j)(2)(C) (2012).
2. 21 U.S.C. §§ 301–399f.
3. Pub. L. No. 98-417, 98 Stat. 1585 (1984) (codified as amended in
scattered sections of 21 and 35 U.S.C.).
4. A similar provision applicable to generic animal drugs was enacted as
part of the Generic Animal Drug and Patent Term Restoration Act, Pub. L.
No. 100-670, 102 Stat. 3971 (1988). See also FDC Act § 512(n)(3), 21 U.S.C.
§ 360b(n)(3).
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This article provides the first ever analysis of the FDA’s nearly
thirty-year track record of responding to ANDA suitability petitions
submitted pursuant to FDC Act section 505(j)(2)(C). Part II traces
the history of generic drug development and the petitioned ANDA
from a regulation promulgated shortly before the enactment of the
5
Hatch-Waxman Act on September 24, 1984, to the current statute.
Part III analyzes almost 1300 suitability petitions submitted to the
FDA since September 24, 1984, and provides various data tables on
the number of suitability petitions submitted to and acted on by the
FDA each year from 1984 to 2013, including the annual average
and median timeframes from petition submission to an FDA
6
decision. Part IV suggests some reasons for the decline in the
popularity of the petitioned ANDA as a vehicle for obtaining
7
approval of a generic drug. Finally, Part V recommends that the
FDA implement procedures to meet the statutory ninety-day
deadline for approving or disapproving an ANDA suitability
petition, or that Congress amend the FDC Act to provide the FDA
8
with a more practical deadline to rule on a suitability petition.
II. A HISTORICAL ACCOUNT OF THE “PETITIONED ANDA”
The ANDA suitability petition provisions of the FDC Act are
short and total slightly more than 150 words:
If a person wants to submit an abbreviated application for
a new drug which has a different active ingredient or
whose route of administration, dosage form, or strength
differ from that of a listed drug, such person shall submit
a petition to the Secretary seeking permission to file such
an application. The Secretary shall approve or disapprove
a petition submitted under this subparagraph within
ninety days of the date the petition is submitted. The
Secretary shall approve such a petition unless the
Secretary finds—
(i) that investigations must be conducted to show the
safety and effectiveness of the drug or of any of its
active ingredients, the route of administration, the
dosage form, or strength which differ from the listed
drug; or
5.
6.
7.
8.

See infra Part II.
See infra Part III.
See infra Part IV.
See infra Part V.
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(ii) that any drug with a different active ingredient
may not be adequately evaluated for approval as safe
and effective on the basis of the information required
9
to be submitted in an abbreviated application.
Although the statutory text for the petitioned ANDA is short,
the historical context in which the petitioned ANDA was created
and developed is not. A broader understanding of the historical
milieu leading up to the enactment of the Hatch-Waxman Act, and
the provisions of that Act governing generic drug approval, are
necessary to understand the development of the petitioned ANDA.
A.

The Hatch-Waxman Regulatory Pathway
10

The first generic drugs were those marketed during the
11
period between the enactment of the FDC Act in 1938 and the
12
enactment of the Drug Amendments of 1962 without FDA
approval, on the theory that the FDA’s approval of the brand-name
drug (also referred to as a pioneer drug) under a New Drug
Application (NDA) based only on safety made the next version an
13
“old” drug. In the period after 1962, the FDA required the

9. FDC Act § 505(j)(2)(C), 21 U.S.C. § 355(j)(2)(C).
10. The term “generic drug” is not defined in the FDC Act or in the FDA’s
regulations. It is used, however, generally to refer to a drug product with the same
active ingredient as a brand-name drug.
11. FDC Act, ch. 675, 52 Stat. 1040 (1938).
12. Pub. L. No. 87-781, 76 Stat. 780.
13. The 1962 Drug Amendments also required the FDA to evaluate the
effectiveness of drug products approved as safe between June 25, 1938, and
October 10, 1962. The FDA engaged the National Academy of Science/National
Research Council (NAS/NRC) to evaluate the effectiveness of the more than 3400
products approved based upon safety. The NAS/NRC review was broken down
into specific drug categories. Review results were submitted to the FDA, which
then reviewed and reevaluated the NAS/NRC findings and published its own
findings in the Federal Register. The FDA’s administrative implementation of the
NAS/NRC reports is called the Drug Efficacy Study Implementation (DESI)
program. DESI covered the products specifically reviewed by the NAS/NRC, as
well as the even larger number of Identical, Related, or Similar (IRS) products
that had entered the market without FDA approval. See 21 C.F.R. § 310.6(b)(1)
(2009) (defining “IRS” drugs). If the FDA’s final determination classified a drug as
effective for its labeled indications, the Agency frequently required sponsors of
approved NDAs (referred to as “deemed approved” NDAs) to supplement their
applications for continued marketing of the drug, and sponsors of IRS drugs to
submit ANDAs seeking approval. If the FDA’s final determination classified a drug
as ineffective, then, because DESI products were covered by “deemed approved”
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submission of an ANDA for each generic drug, but did not permit
ANDAs to be submitted for brand-name drugs approved after
14
1962. This meant that a second version of a post-1962 brand-name
drug had to obtain full NDA approval. A full NDA was economically
prohibitive.
Competitive pressure drove some generic drug companies to
market both pre- and post-1962 drugs without FDA approval,
arguing that an active ingredient became available as an “old” drug
after initial FDA approval. The FDA’s attempts to suppress this
practice culminated in the 1983 Supreme Court decision United
15
States v. Generix Drug Corp. The Court accepted the FDA’s position
that “old drug” status applied not to the active ingredient, but to
the individual finished product. Hence, each new version of a drug
16
was a “new drug” requiring FDA approval no matter how many
17
times the FDA had approved its active ingredient.
Aware that the Agency’s own policies and interpretations were
preventing generic competition for post-1962 drugs, the FDA took
two steps: (1) the development of the so-called “paper NDA” policy
and (2) the development of ANDA regulations for post-1962 drug
products. In 1978, the FDA adopted the “paper NDA” policy, under
which the Agency accepted a combination of product-specific data
and published literature about an active ingredient in satisfaction
18
of the approval requirements for a full NDA. The FDA’s “paper
NDAs, the Agency was required to follow administrative hearing procedures to
withdraw the NDA.
14. See 35 Fed. Reg. 6574 (Apr. 24, 1970).
15. 460 U.S. 453 (1983).
16. A product that is a “new drug” within the meaning of FDC Act section
201(p) may not be introduced into interstate commerce unless there is an
approved marketing application (e.g., an NDA), or unless an exemption has been
granted permitting the introduction of the drug into interstate commerce (e.g.,
an effective Investigational NDA).
17. Over-the-counter drug products marketed pursuant to a monograph are
an exception to this rule. See 21 C.F.R. pt. 330 (2013).
18. See NDAs for Duplicate Drug Products of Post-1962 Drugs, 46 Fed.
Reg. 27,396 (May 19, 1981). The “paper NDA” policy is described in a July 31,
1978 FDA staff memorandum. The policy was not originally published in the
Federal Register because the FDA determined that rulemaking procedures were not
required because “the policy is a lawful exercise of [the] FDA’s statutory authority”
45 Fed. Reg. 82,052 (Dec. 12, 1980). The FDA was challenged on this issue in
court and won. See Burroughs Wellcome Co. v. Schweiker, 649 F.2d 221, 225 (4th
Cir. 1981). Subsequently, in separate litigation, the United States District Court for
the Northern District of Illinois ruled that upon publication of the FDA’s policy in
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NDA” policy essentially permitted the sponsor of an application for
a “duplicate” of a post-1962 drug product (i.e., a drug product that
contained the same active ingredients as an already marketed
product, in a similar or identical dosage form, and for the same
indications) to submit published studies and “bridging” data in
19
support of its application. However, because the “paper NDA”
approach required published literature rather than information
20
not publicly available, it had limited utility for most drugs.
In 1978, the FDA also issued proposed regulations in which
the Agency expressed its intent to extend its pre-1962 ANDA
21
regulations to post-1962 drugs. The FDA began to develop these
regulations in the early 1980s, but never published them. The
FDA’s initiative was controversial because it reportedly would have
required a substantial waiting period after initial approval of the
brand-name drug before any ANDA could be approved for a
generic version. Congressional interest in the FDA’s initiative,
however, coincided with a broader effort to develop legislation that
would promote both competition and innovation in the
22
pharmaceutical industry.

the Federal Register, the Agency could implement it without rulemaking procedures.
See Am. Critical Care v. Schweiker, No. 81-C-252, 1981 Dist. Lexis 12363 (N.D. Ill.
May 13, 1981).
19. The published studies requirement could be met by referencing data
available in published literature, laboratory reports, physician evaluation forms,
and even unpublished reports when available and necessary. However, the
underlying data did not have to be included or referenced, as was required under
the FDA’s old interpretation of “full reports” in FDC Act section 505(b)(1).
Reference to information not publicly available was not permitted, including
information in the innovator product’s NDA. The “bridging” data requirement
could be met by submitting data from a bioavailability/bioequivalence study
comparing the drug that was the subject of the “paper NDA” to the approved drug
“to show that the drug is comparable in blood levels (or dissolution rate, as
required) to the innovator’s product.” NDAs for Duplicate Drug Products of Post1962 Drugs, 46 Fed. Reg. at 27,397.
20. The FDA revoked the “paper NDA” policy in 1989 when the Agency
proposed regulations implementing the Hatch-Waxman Act. See Abbreviated New
Drug Application Regulations, 54 Fed. Reg. 28,872, 28,890 (proposed July 10,
1989).
21. See Abbreviated New Drug Applications, 43 Fed. Reg. 39,126, 39,128
(proposed Sept. 1, 1978).
22. See, e.g., Drug Regulation Reform Act, H.R. 2217, 96th Cong. (1979);
Drug Regulation Reform Act, H.R. 12980, 95th Cong. (1978).

http://open.mitchellhamline.edu/wmlr/vol40/iss4/3

6

Karst: Letting the Devil Ride: Thirty Years of ANDA Suitability Petition

1266

WILLIAM MITCHELL LAW REVIEW

[Vol. 40:4

The FDA’s extended approval process after 1962 undercut the
value of drug patents, which are granted early in the development
process, and much of their then-seventeen-year term from issuance
(now twenty-year term from filing) was eaten up before the FDA
granted marketing approval. Congress engineered a compromise
in which brand-name drug companies could obtain a patent term
extension and generic drug companies could obtain ANDA
approval for pre- and post-1962 drugs. The compromise was
23
enacted on September 24, 1984, as the Hatch-Waxman Act.
The Hatch-Waxman Act resulted from years of legislative effort
and pharmaceutical industry engagement. The goals of this
legislation were: (1) to provide a shortened, predicable pathway for
manufacturers to more quickly market generic versions of brandname drugs; (2) to restore some of the patent protection that
innovator drug developers often lost while their products were
under FDA review; and (3) to substantially lower the cost to
consumers of drugs the FDA has determined do not require
24
additional safety and effectiveness testing.
The Hatch-Waxman Act amended, among other things, the
new drug approval provisions of the FDC Act to add
25
section 505(j). Section 505(j) formalized the legal structure for
generic drugs, under which an ANDA containing bioequivalence
data to a brand-name drug—i.e., the RLD, which is defined as “the
listed drug identified by [the] FDA as the drug product upon which
an applicant relies in seeking approval of its abbreviated
26
application” —among other data and information, was sufficient
for the FDA to consider approval. The Hatch-Waxman Act also
amended the new drug approval provisions of the FDC Act to add
section 505(b)(2) in an attempt to codify the FDA’s “paper NDA”
27
policy and the patent laws to authorize a patent term extension
23. Pub. L. No. 98-417, 98 Stat. 1585 (1984) (codified as amended in
scattered sections of 21 and 35 U.S.C.).
24. See H.R. REP. NO. 98-857, pt. 2, at 14 (1984), reprinted in 1984
U.S.C.C.A.N. 2686, 2698.
25. 21 U.S.C. § 355(j) (2012).
26. 21 C.F.R. § 314.3(b) (2013).
27. A section 505(b)(2) application differs from a “paper NDA” in that it
permits the sponsor of a drug that may differ substantially from a drug listed in the
FDA’s Orange Book to rely on the FDA’s determination of the safety and
effectiveness of a listed drug and/or on published studies or studies in an NDA (or
NDAs) sponsored by another person, together with studies generated on its own
drug product, as a way to satisfy the requirement of “full reports” of safety and
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for time lost during the regulatory review period and to permit a
safe harbor for generic drug companies to perform research and
29
tests in preparation of regulatory approval.
The premise of FDC Act section 505(j) is that an ANDA drug is
the “same as” the brand-name RLD. However, differences are
allowed in route of administration, dosage form, and strength, as
well as in an active ingredient in a combination drug product.
Those differences must first be approved by the FDA under
30
a suitability petition as not requiring clinical investigations.
31
Section 505(j)(2)(A) states that an ANDA that is not the subject of
an approved suitability petition must contain information to show,
among other things, that the active ingredient, “the route of
administration, the dosage form, and the strength of the new drug
32
are the same as those of the [RLD].”
An ANDA must contain, among other things identified in the
33
FDC Act and in the FDA’s ANDA format and content regulations,
information demonstrating that the generic version is
34
bioequivalent to the RLD. This information may come from in
35
vivo (human) and/or in vitro (test tube) studies. The purpose of
demonstrating bioequivalence is to determine whether a proposed
drug product’s formulation or manufacturing affect the rate or
extent to which the active ingredient reaches the primary site of
action. Although data and information demonstrating in vivo
bioequivalence is often required, the FDA may waive this
requirement if in vivo bioequivalence is considered self-evident, or
36
for other reasons.

effectiveness. As with the old “paper NDA” policy, “bridging” studies to the listed
drug are necessary. An application that is for a duplicate of a drug listed in the
Orange Book and eligible for approval under FDC Act section 505(j) may not be
submitted as a section 505(b)(2) application.
28. See 35 U.S.C. § 156 (2006).
29. See id. § 271(e)(1).
30. See FDC Act § 505(j)(2)(C), 21 U.S.C. § 355(j)(2)(C); 21 C.F.R. § 314.93.
31. 21 U.S.C. § 355(j)(2)(A) (2012).
32. FDC Act § 505(j)(2)(A)(iii), 21 U.S.C. § 355(j)(2)(A)(iii).
33. See generally 21 C.F.R. § 314.94.
34. See FDC Act § 505(j)(2)(A)(iv), 21 U.S.C. § 355(j)(2)(A)(iv). The term
“bioequivalence” is defined in the FDC Act and the FDA’s regulations. See FDC Act
§ 505(j)(8)(B), 21 U.S.C. § 355(j)(8)(B); 21 C.F.R. § 320.1(e).
35. See generally 21 C.F.R. § 320.
36. See id. § 320.22.
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Under the FDC Act, ANDA approval is subject to several
restrictions. First, the Hatch-Waxman Act included nonpatent
marketing exclusivity provisions of three or five years to
compensate brand-name drug companies for allowing reliance on
37
their proprietary research. Second, as explained below, an ANDA
applicant must notify an NDA holder and patent owner if a patent
listed in the FDA’s Approved Drug Products with Therapeutic
Equivalence Evaluations (commonly referred to as the “Orange
Book” because of its orange cover) claims the RLD; if the NDA
owner timely files a patent infringement suit, approval of the
ANDA could be delayed. Third, an ANDA drug product must
contain the “same” active ingredient as the brand-name drug and
have essentially the same labeling, including indications, warnings,
contraindications, etc.
The FDC Act and FDA regulations require each NDA sponsor
to submit with its application
the patent number and the expiration date of any patent
which claims the drug for which the applicant submitted
the [NDA] or which claims a method of using such drug
and with respect to which a claim of patent infringement
could reasonably be asserted if a person not licensed by
the owner engaged in the manufacture, use, or sale of the
38
drug.
FDA regulations clarify that “such patents consist of drug
substance (active ingredient) patents, drug product (formulation
39
and composition) patents, and method-of-use patents.” Thus, in
order to list a patent in the Orange Book: (1) the patent must
claim the drug or a method of using the drug that is the subject of
the NDA; and (2) a claim of patent infringement could reasonably
be asserted by the NDA holder or patent owner for the
unauthorized manufacture, use, or sale of the drug that is the
40
subject of the NDA.

37. See FDC Act § 505(c)(3)(E)(j)(5)(F), 21 U.S.C. § 355(c)(3)(E)(j)(5)(F).
38. FDC Act § 505(b)(1), 21 U.S.C. § 355(b)(1).
39. 21 C.F.R. § 314.53(b)(1).
40. See Applications for FDA Approval to Market a New Drug: Patent
Submission and Listing Requirements and Application of 30-Month Stays on
Approval of Abbreviated New Drug Applications Certifying That a Patent Claiming
a Drug Is Invalid or Will Not Be Infringed, 68 Fed. Reg. 36,676 (June 18, 2003)
(codified at 21 C.F.R. pt. 314).
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Once an NDA is approved, the FDA is required to publish
information in the Orange Book on the patents claiming the drug
41
or a method of using it. If a new patent meeting the requirements
of FDC Act § 505(b)(1) and the FDA’s patent listing regulations is
issued while an NDA is pending FDA review or after NDA approval,
the NDA sponsor is required to submit information on the patent
42
to the FDA within thirty days of issuance.
An ANDA for a generic version of an innovator drug must
contain one of four possible certifications “with respect to each
patent which claims the [innovator] drug . . . or which claims a use
for such listed drug . . . and for which information is required to be
43
filed” by the NDA holder which is listed in the Orange Book. If
there are patents on the drug, and the ANDA applicant does not
want to challenge one or more of them, then the applicant submits
a “Paragraph III” certification to each patent it does not want to
challenge, and the FDA cannot approve the application until the
44
patents have expired. If a patent has already expired, or if the
required patent information has not been filed, then the ANDA
applicant submits a “Paragraph II” or “Paragraph I” certification,
45
respectively. If the ANDA applicant wants to challenge a patent
listed in the Orange Book, then the applicant submits a “Paragraph
IV” certification, claiming that the “patent is invalid or will not be
infringed by the manufacture, use, or sale of the new drug for
46
which the [ANDA] is submitted.”
As an alternative to these four certifications, if the listed drug
is covered by an Orange Book–listed “method of use patent which
does not claim a use for which the [ANDA] applicant is seeking
approval,” then the application must contain “a statement that the
47
method of use patent does not claim such a use.” This is often
referred to as a “section viii statement” and it permits a generic
applicant to “carve out” of its proposed labeling a patent-protected
41. See FDC Act § 505(b)(1), (c)(2), 21 U.S.C. § 355(b)(1), (c)(2).
42. See FDC Act § 505(c)(2), 21 U.S.C. § 355(c)(2); see also 21 C.F.R.
§ 314.53(c)(2)(ii), (d)(1) and (d)(3).
43. FDC Act § 505(j)(2)(A)(vii), 21 U.S.C. § 355(j)(2)(A)(vii).
44. See FDC Act § 505(j)(2)(A)(vii)(III), (j)(5)(B)(ii), 21 U.S.C. § 355(j)(2)
(A)(vii)(III), (j)(5)(B)(ii).
45. See FDC Act § 505(j)(2)(A)(vii)(I)–(II), (j)(5)(B)(i), 21 U.S.C. § 355(j)
(2)(A)(vii)(I)–(II), (j)(5)(B)(i).
46. FDC Act § 505(j)(2)(A)(vii)(IV), (j)(5)(B)(iii), 21 U.S.C. § 355(j)(2)
(A)(vii)(IV), (j)(5)(B)(iii).
47. FDC Act § 505(j)(2)(A)(viii), 21 U.S.C. § 355(j)(2)(A)(viii).
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use, provided that the omission of such protected information does
not “render the proposed drug product less safe or effective than
48
the listed drug for all remaining, nonprotected conditions of use.”
A generic applicant making a Paragraph IV certification must
notify the NDA holder and patent owner that an application has
been submitted to the FDA, once the Agency determines that the
ANDA is substantially complete. The notice must include a
“detailed statement of the factual and legal basis of the opinion of
the applicant that the patent is invalid or will not be infringed,”
and must “state that an application . . . has been submitted . . . for
the drug with respect to which the certification is made to obtain
approval to engage in the commercial manufacture, use, or sale of
the drug before the expiration of the patent referred to in the
49
certification.”
The NDA holder or patent owner has forty-five days from the
date of receipt of such notice to file a suit for patent
50
infringement. If a patent infringement suit is brought by the NDA
holder or the patent owner within the forty-five day period, then
the FDA cannot approve the ANDA until the earlier of: (1) the
expiration of a single thirty-month stay of approval, which may be
shortened or lengthened by the court if “either party to the action
51
fail[s] to reasonably cooperate in expediting the action”; (2) the
date on which a district court enters judgment in favor of the
defendant (i.e., the ANDA applicant) that the patent is invalid or
not infringed (or on the date of a settlement order or consent
decree signed and entered by the court stating that the patent that
52
is the subject of the certification is invalid or not infringed);

48. 21 C.F.R. § 314.127(a)(7) (2013). An ANDA applicant must make an
additional certification (or submit an additional “section viii statement”) as to any
new patent listed in the Orange Book while its application is pending if the NDA
holder submits the new patent to the FDA for Orange Book listing within thirty
days of patent issuance. See id. § 314.94(a)(12)(vi). Post-MMA, a Paragraph IV
certification to a later-listed patent will not result in an additional thirty-month stay
of ANDA approval. See FDC Act § 505(c)(2), 21 U.S.C. § 355(c)(2); see also
21 C.F.R. § 314.53(c)(2)(ii).
49. FDC Act § 505(j)(2)(B)(ii), 21 U.S.C. § 355(j)(2)(B)(ii).
50. See FDC Act § 505(j)(5)(B)(iii), 21 U.S.C. § 355(j)(5)(B)(iii).
51. Id.
52. The statutory language regarding settlement orders and consent
decrees was added post-MMA. Compare FDC Act § 505(j)(5)(B)(iii), 21 U.S.C.
§ 355(j)(5)(B)(iii) (2002), with FDC Act § 505(j)(5)(B)(iii), 21 U.S.C. § 355(j)
(5)(B)(iii) (2012).
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or (3) if the district court enters judgment in favor of the plaintiff
(i.e., the NDA holder or patent owner) and that decision is
appealed by the ANDA applicant, the date on which the court of
appeals enters judgment in favor of the ANDA applicant that the
patent is invalid or not infringed (or on the date of a settlement
order or consent decree signed and entered by the court of appeals
stating that the patent that is the subject of the certification is
53
invalid or not infringed).
If the judgment of the district court is not appealed or is
affirmed by the court of appeals, then the approval will be made
effective on the date specified by the district court in a court
54
order. If a patent infringement suit is not brought by the NDA
holder or the patent owner within the forty-five-day period, then
55
the FDA can approve the ANDA at any time.
The Hatch-Waxman Act established an incentive for generic
manufacturers to submit Paragraph IV certifications and to
challenge Orange Book–listed patents as invalid or not infringed,
56
by providing for a 180-day period of marketing exclusivity. This
means, in certain circumstances, an applicant who submits the first
ANDA containing a Paragraph IV certification to an Orange Book–
listed patent is protected from competition from other generic
versions of the same drug product for 180 days. Prior to the
December 2003 enactment of the Medicare Prescription Drug,
57
Improvement, and Modernization Act of 2003 (MMA), 180-day
exclusivity was patent-based, such that a period of 180-day
exclusivity could arise from each Orange Book–listed patent. PreMMA, 180-day exclusivity began on (i.e., was triggered by) the
earlier of the date the FDA “receive[d] notice from the
applicant . . . of the first commercial marketing of the drug” under
the first ANDA or “the date of a decision of a court in [a patent
infringement action] holding the patent which is the subject of the
58
certification to be invalid or not infringed.”

53. FDC Act § 505(j)(5)(B)(iii)(II)(aa), 21 U.S.C. § 355(j)(5)(B)(iii)(II)(aa)
(2012).
54. FDC Act § 505(j)(5)(B)(iii)(II)(bb), 21 U.S.C. § 355(j)(5)(B)(iii)(II)
(bb).
55. FDC Act § 505(j)(5)(B)(iii), 21 U.S.C. § 355(j)(5)(B)(iii).
56. See Abbreviated New Drug Application Regulations, 54 Fed. Reg. 28,894
(proposed July 10, 1989).
57. Pub. L. No. 108-173, 117 Stat. 2066 (2003).
58. FDC Act § 505(j)(5)(B)(iv), 21 U.S.C. § 355(j)(5)(B)(iv)(I) (2000).
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Post-MMA, 180-day exclusivity is generally product-based, such
that there is a single 180-day exclusivity period with respect to each
listed drug. Only a “first applicant”—“an applicant that, on the first
day on which a substantially complete application containing a
[Paragraph IV Certification] is submitted for approval of a drug,
submits a substantially complete application that contains and
lawfully maintains a [Paragraph IV Certification] for the drug”—
59
can qualify for 180-day exclusivity. Post-MMA, there is only a single
trigger to 180-day exclusivity: first commercial marketing. A first
applicant that qualifies for 180-day exclusivity can forfeit eligibility
60
for such exclusivity under various circumstances.
An ANDA subject to an approved suitability petition is treated
like any conventional ANDA not requiring the approval of a
suitability petition submitted pursuant to section 505(j) of the FDC
Act. That is, an ANDA subject to an approved suitability petition
must contain a certification to each Orange Book–listed patent
covering the RLD, is subject to a thirty-month stay of approval, and
is eligible for a period of 180-day exclusivity vis-à-vis subsequent
Paragraph IV ANDA filers for the same drug product approved
61
under the applicable suitability petition.
Once the FDA approves an ANDA, information about the drug
product is added to the FDA’s Orange Book, including whether or
not the approved generic drug is considered a “therapeutic
equivalent” to, and thus substitutable for, the brand-name RLD
relied on for approval. The term “therapeutic equivalence” is not
defined in the FDC Act or in FDA ANDA regulations; however,
“[d]rug products are considered to be therapeutic equivalents only
if they are pharmaceutical equivalents and if they can be expected to
have the same clinical effect and safety profile when administered

59. FDC Act § 505(j)(5)(B)(iv)(II)(bb), 21 U.S.C. § 355(j)(5)(B)(iv)(II)(bb)
(2012).
60. See generally FDC Act § 505(j)(5)(D)(i)(I)–(VI), 21 U.S.C. § 355(j)(5)
(D)(i)(I)–(VI) (2012) (listing failure to market the drug within a specified
timeframe, withdrawing the application, amending or withdrawing patent
certification, failing to obtain tentative approval, entering an agreement with
another applicant, and expiration of patent).
61. See, e.g., FOOD & DRUG ADMIN., ANDA 76-642/S-005, S-006, S-007 and
S-008, LETTER (Oct. 19, 2007) (Hydrocodone Bitartrate and Ibuprofen Tablets,
2.5 mg/200 mg (new strength)); FOOD & DRUG ADMIN., ANDA 77-660, LETTER
(July 31, 2007) (Escitalopram Oxalate Capsules, 5 mg (base), 10 mg (base) and
20 mg (base) (new dosage form)).
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to patients under the conditions specified in the labeling” (i.e., bio62
equivalent).
FDA regulations define the term “pharmaceutical equivalents”
to mean “drug products in identical dosage forms that contain
identical amounts of the identical active drug ingredient . . . that
deliver identical amounts of the active drug ingredient over the
63
identical dosing period.”
Because therapeutic equivalence
requires that two drug products be pharmaceutically equivalent in
order to be substitutable, “pharmaceutical alternatives” are not
therapeutic equivalents and are not substitutable for the RLD
relied on for approval. Pharmaceutical alternatives are “drug
products that contain the identical therapeutic moiety, or its
precursor, but not necessarily in the same amount or dosage form
64
or as the same salt or ester.” Thus, products approved pursuant to
an approved suitability petition are pharmaceutical alternatives and
are not listed in the Orange Book as therapeutically equivalent to,
and substitutable for, the RLD.
B.

The Development of the Petitioned ANDA

As discussed above, even before the enactment of the HatchWaxman Act in 1984, the FDA had already created by regulation
and under Agency policy approval processes for generic drugs:
ANDAs for generic version of drug products approved under NDAs
prior to 1962, and “paper NDAs” for versions of drug products
approved post-1962 under an NDA. It was in this milieu that the
petitioned ANDA was also created.
In 1978, the FDA proposed regulations to limit the availability
of the then-existing ANDA procedures, generally, to drug products
approved under an NDA between 1938 and 1962 subject to a Drug
Efficacy Study Implementation (DESI) program finding if the
proposed generic version was the same as (i.e., identical to) the
NDA-approved drug product in terms of dosage form, strength,

62. FOOD & DRUG ADMIN., APPROVED DRUG PRODUCTS WITH THERAPEUTIC
EQUIVALENTS, at vii (34th ed. 2014) (emphasis added) (commonly known as “The
Orange Book”). “[The] FDA believes that products classified as therapeutically
equivalent can be substituted with the full expectation that the substituted product
will produce the same clinical effect and safety profile as the prescribed product.”
Id.
63. 21 C.F.R. § 320.1(c) (2013).
64. Id. § 320.1(d).
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route of administration, active ingredient, and conditions of use.
Specifically, the FDA proposed to amend the Agency’s new drug
regulations to provide:
A finding by the Commissioner of Food and Drugs that an
[ANDA] is appropriate for a drug product is limited to
products that are the same in dosage form, route of
administration, kind and amount of active ingredient,
indication(s), and any other conditions of use as the drug
product that was the subject of the finding. A determination that an [ANDA] is the appropriate form of
application for a drug product does not apply to a similar
or related drug product unless the notice of that finding
specifies that it applies to a particular similar or related
66
product and that product is described.
This limitation on the availability of the ANDA procedures was
necessary because, according to the FDA, “applicants continue to
submit ANDA’s [sic] for products clearly not subject to the finding
67
in a DESI notice that an ANDA is appropriate.” As the FDA
further explained, the Agency’s findings of safety and effectiveness
for an NDA-approved drug are generally drug-product specific. A
change, such as a different strength or route of administration,
“may affect the safety or the effectiveness of the related product or
at least raise a question about safety or effectiveness that cannot be
68
answered without additional data.”
To reach a conclusion on whether the FDA’s previous finding
of safety and effectiveness could extend to a nonidentical version of
the NDA-approved drug, the FDA proposed the creation of an
administrative procedure, allowing prospective ANDA applicants to
petition the FDA pursuant to the Agency’s citizen petition
procedures at 21 C.F.R. § 10.30 to submit an ANDA for a drug
69
product similar or related to an NDA-approved drug product. The
70
FDA’s proposal was finalized in January 1983 and heralded in the
era of the ANDA suitability petition. Under the FDA’s final rule,
the Agency would accept an ANDA “only if it has made a finding
71
that an abbreviated application is suitable for the drug product.”
65.
66.
67.
68.
69.
70.
71.

See 43 Fed. Reg. 39,126 (proposed Sept. 1, 1978).
Id. at 39,129.
Id. at 39,128.
Id. at 39,127.
See id.
See 48 Fed. Reg. 2751 (Jan. 21, 1983).
21 C.F.R. § 314.2(b)(1) (1984).
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An FDA finding that an ANDA “is suitable for a drug product . . .
that is the same in active ingredient, dosage form and strength,
route of administration, and conditions of use as the drug product
72
that was the subject of the finding.” “For a drug product that was
similar but different in one or more of these characteristics,”
however, the FDA regulation provided that “an [ANDA] will be
accepted [for review] only if [FDA] has made a separate finding of
73
suitability.” As the regulation further explained:
A prospective applicant may seek a determination of the
suitability of an [ANDA] for a product that the applicant
believes similar or related to a drug product that has been
declared to be suitable for an [ANDA]. Extension of the
finding that a drug product is safe and effective to
another product will ordinarily be limited to other dosage
forms for the same route of administration or to closely
related ingredients. If preclinical or clinical evidence is
needed to support the safety, or if clinical evidence is
needed to support the effectiveness, of the proposed
product, then an [ANDA] is not suitable for the similar or
74
related drug product.
To obtain an FDA finding of ANDA suitability, the Agency
instructed prospective applicants to submit a citizen petition in
which “[t]he petitioner shall set forth the reasons that justify
extending the finding that an [ANDA] is suitable for one product
75
to the similar or related product proposed to be marketed.” The
FDA also required each ANDA submitted to the Agency “to contain
a reference to the finding of the [FDA] that an abbreviated
application is suitable for the specific product that is the subject of
76
the application.” Notwithstanding the detailed nature of the

72. Id. § 314.2(b)(2).
73. Id.
74. Id. § 314.2(c).
75. Id. § 314.2(d). The regulation further provides that “[a] new drug
application submitted in the form of an [ANDA] for a drug product that has not
been the subject of a finding that allows an abbreviated application for the
product will be considered to be a petition under § 10.30 of this chapter and will
be processed as such.” Id. § 314.2(e).
76. Id. § 314.2(f). In 1985, the FDA completed a revision and reorganized
certain of the Agency’s regulations and moved § 314.2 to 21 C.F.R. § 314.55.
See New Drug and Antibiotic Regulations, 50 Fed. Reg. 7452, 7466 (Feb. 22, 1985).
Section 314.55 was removed in 1992 with the promulgation of final regulations
implementing the ANDA provisions of the Hatch-Waxman Amendments.
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FDA’s final rule, it did not specify any timeframe or deadline for
the FDA to approve or disapprove a suitability petition.
Slightly more than a year and nine months after the FDA
promulgated its ANDA suitability petition regulations, the HatchWaxman Act was enacted and created the contemporary ANDA
procedures applicable to generic versions of all FDA-approved
drugs. Among other things, the Hatch-Waxman Act effectively
codified the suitability petition procedures that the FDA had
77
promulgated.
In creating the ANDA suitability petition process, Congress
noted that four types of changes are permitted to be made by a
suitability petition—a change in dosage form, strength, route of
administration, or, in the case of a combination drug product, a
change in one active ingredient—and that these are “the only
changes from the listed drug for which an applicant may petition
78
[the FDA].” Congress also, however, wisely added a requirement
that the FDA timely rule on ANDA suitability petitions. Under the
statute, the FDA “shall approve or disapprove a petition . . . within
79
ninety days of the date the petition is submitted” to the Agency.
The FDA issued proposed regulations in 1989 to implement
80
the Hatch-Waxman Act, and finalized those regulations regarding
81
ANDA submission and approval in 1992. The regulations
concerning ANDA suitability petitions, which are located at
82
21 C.F.R. § 314.93, were finalized with relatively little opposition.
The regulations detail the content and format of a suitability
83
petition, the conditions under which the FDA will approve or
See Abbreviated New Drug Application Regulations, 57 Fed. Reg. 17,950, 17,983
(Apr. 28, 1992).
77. Hatch-Waxman Act, Pub. L. No. 98-417, 98 Stat. 1585, 1587 (1984)
(codified as amended at 21 U.S.C. § 355(j)(2)(C) (2012)).
78. H.R. REP. NO. 98-857, pt. 1, at 23 (1984), reprinted in 1984 U.S.C.C.A.N.
2647, 2656. As an alternative to submitting an ANDA subject to an approved
suitability petition for these types of changes, a company may instead submit a
section 505(b)(2) application. See FOOD & DRUG ADMIN., DRAFT GUIDANCE FOR
INDUSTRY, APPLICATIONS COVERED BY SECTION 505(B)(2), at 4 (1999).
79.
21 U.S.C. § 355(j)(2)(C) (2012).
80. See Abbreviated New Drug Application Regulations, 54 Fed. Reg. 28,872
(proposed July 10, 1989).
81. See Abbreviated New Drug Application Regulations, 57 Fed. Reg. 17,950
(April 28, 1992).
82. See id. at 17,951–52 (discussing the FDA’s decision to make suitability
petitions publicly available).
83. See 21 C.F.R. § 314.93(a)–(d) (2013).
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disapprove a suitability petition within ninety days after sub84
mission, and when the FDA may withdraw approval of a suitability
85
petition.
There are no binding rules governing the FDA’s procedures in
processing ANDA suitability petitions. The FDA’s normal
procedure has been to have a petition first go to the Office of
Generic Drugs (OGD), which is responsible for preparing a
synopsis of the petition and providing its views on appropriate
resolution to the FDA’s Suitability Petition Committee. The
committee either approves the action on the petition
recommended by the OGD or refers the matter to other FDA
components for further review. Once a decision is prepared and, if
necessary, reviewed by the FDA’s office of chief counsel, the
86
approval or denial is sent to the petitioner by the OGD.
From the enactment of the Hatch-Waxman Act until 2003, the
FDA’s consideration of and action on ANDA suitability petitions,
although slow, was not generally affected by other changes in the
law. That changed with the December 3, 2003 enactment of the
87
Pediatric Research Equity Act of 2003 (PREA). PREA amended
88
the FDC Act to add new section 505B. It significantly affected the
FDA’s previous ANDA suitability petition decisions and the
Agency’s ability to approve future suitability petitions for certain
proposed changes.
89
PREA essentially codified the FDA’s 1998 “Pediatric Rule.”
Under the Pediatric Rule, in order to promote more
comprehensive pediatric testing and labeling, the FDA required

84. See id. § 314.93(e).
85. See id. § 314.93(f) (“[The] FDA may withdraw approval of a petition if the
[A]gency receives any information demonstrating that the petition no longer
satisfies the conditions under paragraph (e) of this section.”).
86. See generally CTR. FOR DRUG EVALUATION & RESEARCH, FOOD DRUG
ADMIN., MAPP 5240.5 MANUAL OF POLICIES AND PROCEDURES: OFFICE OF GENERIC
DRUGS ANDA SUITABILITY PETITIONS (2013), available at http://www.fda.gov
/downloads/AboutFDA/CentersOffices/OfficeofMedicalProductsandTobacco
/CDER/ManualofPoliciesProcedures/UCM365676.pdf.
87. Pub. L. No. 108-155, 117 Stat. 1936 (codified as amended at 21 U.S.C.
§§ 284m, 355–355c (2012)).
88. Id. § 2, 117 Stat. at 1936 (codified as amended at 21 U.S.C. § 355c).
89. See Regulations Requiring Manufacturers to Assess the Safety and
Effectiveness of New Drugs and Biological Products in Pediatric Patients, 63 Fed.
Reg. 66,632 (Dec. 2, 1998) (codified at 21 C.F.R. §§ 201, 312, 314, 601); see also
21 C.F.R. §§ 201.23, 314.55, 601.27 (1999).
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manufacturers submitting certain applications to evaluate the safety
and effectiveness of their products in pediatric populations, unless
90
the requirement was waived or deferred by the FDA. The Pediatric
Rule became effective on April 1, 1999, but was invalidated in
October 2002 by the United States District Court for the District of
Columbia as exceeding the FDA’s statutory authority under the
91
FDC Act. Legislation was pursued that would enable the FDA to
require pediatric studies for certain applicants, culminating in the
enactment of PREA.
Under PREA as initially enacted, Congress granted the FDA
with the statutory authority to require pediatric studies in certain
92
defined circumstances retroactive to April 1, 1999. Specifically,
the statute states that an applicant “that submits . . . an application
(or supplement to an application) . . . under section [505 of the
FDC Act] for a new active ingredient, new indication, new dosage form,
new dosing regimen, or new route of administration . . . shall submit
with the application” the results of pediatric studies assessing “the
safety and effectiveness of the drug . . . for the claimed indications
in all relevant pediatric subpopulations; and . . . to support dosing
and administration for each pediatric subpopulation for which the
drug . . . is safe and effective,” unless the FDA defers or partially or
93
fully waives this requirement.
An ANDA requiring an approved suitability petition for a
change in the RLD in an active ingredient, route of administration,
or dosage form triggers PREA because it is a type of application
submitted under FDC Act section 505. The only change permitted

90. See Kurt R. Karst, Comment, Pediatric Testing of Prescription Drugs: The Food
and Drug Administration’s Carrot and Stick for the Pharmaceutical Industry, 49 AM. U. L.
REV. 739, 754 (2000).
91. Ass’n of Am. Physicians & Surgeons v. FDA, 226 F. Supp. 2d 204, 222
(D.D.C. 2002).
92. See Pediatric Research Equity Act, §§ 2, 4, 117 Stat. at 1936, 1942; see also
Letter from Gary Buehler, Dir., Office of Generics, FDA Ctr. for Drug Evaluation
& Research, to Richard S. Morey, Att’y, Kleinfeld, Kaplan & Becker (Feb. 11,
2004), available at http://www.fda.gov/ohrms/dockets/dailys/04/June04/061004
/04p-0262-cp00001-Tab-3-vol1.pdf (“PREA applies retroactively to all suitability
petitions submitted on or after April 1, 1999, and affects suitability petitions
already approved as well as those currently pending or not yet submitted.”).
93. FDC Act § 505B(a)(1)–(4), 21 U.S.C. § 355c(a)(1)–(4) (2012) (emphasis
added).
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by a suitability petition that does not trigger PREA is a change in
94
strength from the RLD.
FDC Act section 505(j)(2)(C)(i) requires that the FDA deny a
suitability petition if “investigations must be conducted to show the
safety and effectiveness of the drug or of any of its active
ingredients, the route of administration, the dosage form, or
strength which differ from the listed drug.” The requirement to
conduct (or even a deferral from conducting) pediatric studies
triggers the statutory requirement to deny a suitability petition.
Thus, unless the FDA fully waives the PREA pediatric studies
requirement, the Agency must deny a suitability petition that
requests permission to submit an ANDA for a change in route of
administration, dosage form, or active ingredient vis-à-vis the RLD.
95
The FDA stated this interpretation as early as 2004, and later
withdrew approval of 128 suitability petitions in accordance with
96
PREA.
III. SLOTH: THE FDA’S ANDA SUITABILITY PETITION DECISION
TRACK RECORD
Over the thirty years that the FDA has reviewed and acted on
ANDA suitability petitions, the Agency has fallen victim to one of
the seven deadly sins: sloth. A review of nearly 1300 ANDA
suitability petitions submitted to the FDA since the enactment of
the Hatch-Waxman statutory provision creating them shows that
the FDA has been largely unable to meet the mandatory statutory
ninety-day deadline of approving or disapproving a petition,
particularly in recent years, despite a decline in the number of
petitions submitted to the FDA.
The tables included in the appendix to this article are the
culmination of this author’s review of myriad sources of
94. See FDC Act § 505B(a)(1)(A), 21 U.S.C. § 355c(a)(1)(A) (listing as
affected by PREA, a marketing application for approval of a “new active
ingredient, new indication, new dosage form, new dosing regimen, or new route
of administration”)
95. See Letter from Gary Buehler, supra note 92 (“If the change proposed in
an ANDA suitability petition does not qualify for a full waiver of the pediatric
studies, the approval of that petition will be revoked because, under PREA, clinical
studies are required to demonstrate the safety and or effectiveness of the
change.”).
96. See Withdrawal of Approval of 128 Suitability Petitions, 72 Fed. Reg. 8184
(Feb. 23, 2007).
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information showing citizen petitions submitted to the FDA
between September 24, 1984, and December 31, 2013, and
identified in such records as ANDA suitability petitions. Although
the FDA posts a list of ANDA suitability petitions on the Agency’s
97
website, that list is incomplete. The FDA’s list omits, for example,
approved suitability petitions withdrawn as result of the enactment
of PREA and any suitability petitions submitted before March 31,
1999. In order to form a more complete account of the FDA’s
record of acting on suitability petitions, the author’s analysis
includes such petitions without regard to their ultimate withdrawal
98
of approval as a result of PREA.
For each year from 1984 to 2013, the author tabulated the
number of ANDA suitability petitions submitted to the FDA. Those
results are shown in Table 1 in the appendix to this article. After
tabulating the number of suitability petitions submitted to the FDA
annually, the author examined for each year the number of
petitions the FDA approved and denied, the number of petitions
withdrawn by the petitioner before receiving a substantive response
from the FDA, and the number of petitions that remain pending as
of December 31, 2013. Those results are shown separately in Tables
2–5, with Table 6 showing, in line graph format, the combined data
in Tables 2–5.
Next, the author calculated for each year cohort the average
and median times for the FDA to respond to a petition by either
approving or disapproving the petition, based on the date of
petition submission to the FDA and the date of the Agency’s
response. For this analysis, petitions withdrawn by the petitioner
before an FDA approval or disapproval decision were excluded
from the calculation. In addition, separate calculations were
performed for each year cohort that both exclude and include
97. See Suitability Petitions, FOOD & DRUG ADMIN., http://www.fda.gov/drugs
/developmentapprovalprocess/howdrugsaredevelopedandapproved/approval
applications/abbreviatednewdrugapplicationandagenerics/ucm120944.htm
(last updated Feb. 5, 2014).
98. Omitted from this analysis are sixteen ANDA suitability petitions
submitted to the FDA prior to the September 24, 1984, enactment of the HatchWaxman Act, when the FDA’s suitability petition regulations were in force,
regardless of whether or not the FDA approved or disapproved such petitions after
September 24, 1984. Because the FDA’s suitability petition regulations did not
require the FDA to decide on such petitions within a defined period, there was no
specific expectation at the time of submission that the FDA would approve or
disapprove these petitions within ninety days.
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suitability petitions pending an FDA approval or disapproval
decision as of December 31, 2013.
When including pending petitions, the number of days
pending was calculated based on the day of petition submission to
the FDA and as of December 31, 2013. Those results are shown in
Tables 7–12, with Tables 9 and 12 comparing the average and
median numbers of days to an FDA decision both where pending
petitions are excluded and included, respectively. Because there
are ANDA suitability petitions pending, an FDA decision as far back
as 2001 (Table 6), excluding pending petitions yields actual annual
average and median FDA decision timeframes, and that are
significantly less than the possible annual average and median FDA
decision timeframes calculated when such pending petitions are
included. Ultimately, if such petitions are not withdrawn and are
ruled on by the FDA, then their potentiality will be actualized.
Each table appears, at first blush, to reflect a significant
downward trend in recent years in the average and median times
for the FDA to rule on a suitability petition, regardless of whether
or not pending petitions are included or excluded from the
analysis. The “trend” is somewhat illusory, however, for two related
reasons. First, there are a large number of pending suitability
petitions submitted to the FDA in recent years that the Agency has
not yet approved or disapproved. Second, for purposes of our
analysis, the author needed to institute a cutoff date of December
31, 2013 that is artificial. As such, petitions submitted to the FDA in
recent years but not yet ruled on have not “aged” to the extent that
older petitions—whether or not yet ruled on by the FDA—have
“aged.” If the FDA were to promptly approve or disapprove
pending petitions submitted to the Agency in recent years, then
there would, in fact, be a downward trend in average and median
times. If, however, the FDA allows pending petitions submitted to
the Agency in recent years to languish without a ruling, then the
Agency’s actual decision timeframe will remain high.
One trend that is not illusory is an upward trend in decision
timeframes beginning around 2002 or 2003 and peaking around
2007. The start of this trend generally coincides with the enactment
of PREA, and may reflect additional time taken by the FDA’s OGD
to rule on suitability petitions because of the need to consult other
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FDA components on pediatric testing issues, such as the FDA’s
99
Pediatric Review Committee (PeRC).
Finally, the author consolidates several of the tables above to
show, in Tables 13 and 14, an overview of the numbers of petitions
submitted, withdrawn, and acted on by the FDA vis-à-vis the average
and median figures shown above (in line graph format), both
including and excluding pending petitions. In order to show all of
these data on a single table, the numbers showing average and
median FDA response timeframes (both including and excluding
pending suitability petitions) have been reduced by a factor of ten
(i.e., 100 = 10).
IV. LOSS OF FAITH: POSSIBLE REASONS FOR THE DECLINE IN THE
POPULARITY OF THE PETITIONED ANDA
Two trends in particular stand out when examining the tabular
results presented in Part III of this article: (1) despite initial
excitement, the generic drug industry’s interest in ANDA suitability
petitions has waned, particularly in the past four years; and
(2) despite some early success, the FDA has been unable to meet,
on an annual basis for petitions submitted in each cohort year, the
statutory ninety-day deadline for approving or disapproving ANDA
suitability petitions. Indeed, as shown in Tables 15 and 16, adding
linear trend lines to two of the tables from Part III above clearly
shows the number of ANDA suitability petitions on the downswing
and the FDA’s average and median response times (even excluding
pending petitions) on the upswing.
It is logical to conclude that the two trends are related. The
longer it takes for the FDA to approve or disapprove an ANDA
suitability petition, the less incentive there is for the generic drug
industry to submit such petitions, because it is unknown if the FDA
will rule on the petition in a reasonable timeframe so that a generic
100
drug company can plan its development of a drug accordingly.
99. See generally 21 U.S.C. § 355d (2012) (establishing the PeRC).
100. Curiously, no generic drug company has yet, to this author’s knowledge,
challenged the FDA in court over the Agency’s unreasonable delay in ruling on an
ANDA suitability petition. Nevertheless, there appears to be a basis for such a
challenge under the Administrative Procedures Act (APA), 5 U.S.C. §§ 501–596
(2012), alleging that the FDA failed to perform a nondiscretionary statutory duty
to timely act upon an ANDA suitability petition within ninety days. Indeed, there is
precedent for courts compelling the FDA to act on a mandatory obligation when
plaintiffs have alleged unreasonable delay. In Sandoz, Inc. v. Leavitt, 427 F. Supp.
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In other words, the generic drug industry has lost faith in the
101
ANDA suitability petition process. Part V of this article proposes
how the FDA (or Congress) can redeem the faith of the generic
drug industry in the suitability petition process; however, before
moving on to that final topic, it bears noting that the glacial pace at
which the FDA rules on suitability petitions is not the sole factor for
the generic drug industry’s waning interest in submitting suitability
petitions to the FDA. A couple of other factors are relevant.
102
As discussed in Part II of this article, PREA significantly
affected the FDA’s ability to approve suitability petitions seeking
permission to submit an ANDA for a drug product that deviates
from the RLD in dosage form, route of administration, and active
ingredient in a combination drug product. As a result, fewer
suitability petitions have been submitted to the FDA requesting
permission for such changes. For example, of the twenty-three
suitability petitions submitted to the FDA in 2011, eighteen of them
requested permission to submit an ANDA for a new strength, while
four requested permission for a new dosage form, and one for both
a new strength and new dosage form.
2d 29, 41 (D.D.C. 2006), the plaintiff successfully sued the FDA for not approving
or disapproving its NDA in over 1000 days (over five times the statutory deadline
of 180 days). In In re Barr Laboratories, Inc., 930 F.2d 72, 73 (D.C. Cir. 1991), the
plaintiff sought a writ of mandamus compelling the FDA to either approve or
disapprove twenty-three of Barr’s ANDAs, claiming that the FDA had repeatedly
missed the statutory 180-day deadline. The court did not grant relief to the
plaintiff, finding that granting the writ would only put Barr at the head of the
queue and simply move all others back one space. See id. at 75. The court did,
however, hold that the FDA’s compliance with the 180-day deadline was
mandatory and not merely a policy recommendation. See id. at 76.
101. Whether the FDA has also lost faith in the ANDA suitability petition
process, because of a low “rate of return” on the investment needed to review and
act on suitability petitions, is another factor that may affect the lengthy FDA
decision process. That is, if the FDA is of the mindset that the Agency’s approval of
suitability petitions is not resulting in the submission and approval of ANDAs
based on those decisions, then there is a disincentive for the FDA to promptly
review and rule on suitability petitions. Unfortunately, because specific
information about ANDA submissions is maintained by the FDA as confidential
information, it is impossible to gauge the success of the suitability petition process
by virtue of the number of ANDA submissions made based on an approved
suitability petition, as not all applications submitted to the FDA are approved.
Although it might be possible to tabulate the number of petitioned ANDAs the
FDA has ever approved, this author has not yet attempted to undertake that
monumental task.
102. See supra notes 89–96 and accompanying text.

http://open.mitchellhamline.edu/wmlr/vol40/iss4/3

24

Karst: Letting the Devil Ride: Thirty Years of ANDA Suitability Petition

1284

WILLIAM MITCHELL LAW REVIEW

[Vol. 40:4

Another factor that may affect the number of ANDA suitability
petitions submitted to the FDA annually is the growing popularity
of the section 505(b)(2) NDA as a route to obtain approval of a
drug product that deviates in some respect from a brand-name
drug approved under an NDA. A generic drug manufacturer may
use the section 505(b)(2) NDA route as an alternative to
submitting an ANDA subject to an approved suitability petition for
each of the types of changes permitted via a suitability petition, as
well as myriad other changes not permitted under the ANDA
103
approval route. Indeed, when faced with the decision of either
petitioning the FDA for permission to submit an ANDA, the
submission of which may not occur for several years, or
immediately submitting a section 505(b)(2) NDA to the FDA
without having to first request, and then await, the Agency’s
permission, companies may well choose the latter option. Although
the submission of a section 505(b)(2) application is more costly
104
than an ANDA submission, the FDA is almost certain to take an
105
approval action on a section 505(b)(2) NDA before an ANDA,

103. See FOOD & DRUG ADMIN., supra note 78, at 4.
104. Under the Prescription Drug User Fee Amendments of 2012 (PDUFA) of
the Food and Drug Administration Safety and Innovation Act, Pub. L. No. 112144, tit. I, 126 Stat. 993, 996 (2012), the FDA is authorized to collect user fees for
certain applications for approval of drug and biological products, on
establishments where the products are manufactured, and on such products. The
fee to submit a section 505(b)(2) application to the FDA in fiscal year 2014 that
does not contain clinical data is $1,084,550. See Notice, Prescription Drug User Fee
Rates for Fiscal Year 2014, 78 Fed. Reg. 46,980 (Aug. 2, 2013). Similarly, under the
Generic Drug User Fee Amendments of 2012 (GDUFA), tit. III, 126 Stat. at 1008,
the FDA is authorized to collect user fees for certain applications for approval of a
generic drug, among other types of fees. The fiscal year 2014 ANDA fee is $63,860.
See Notice, Generic Drug User Fee—Abbreviated New Drug Application, Prior
Approval Supplement, Drug Master File, Final Dosage Form Facility, and Active
Pharmaceutical Ingredient Facility Fee Rates for Fiscal Year 2014, 78 Fed.
Reg. 46,977 (Aug. 2, 2013).
105. Under the latest iteration of PDUFA, the FDA agreed to act on ninety
percent of the NDAs typically submitted to the Agency within either ten months of
the receipt date (standard applications) or within six months of the receipt date
(priority applications). See Food & Drug Admin., PDUFA Reauthorization Performance
Goals and Procedures Fiscal Years 2013 Through 2017, http://www.fda.gov/downloads
/ForIndustry/UserFees/PrescriptionDrugUserFee/UCM270412.pdf (last visited
Apr. 28, 2014). Under GDUFA, the FDA has agreed to certain performance goals
concerning ANDA approval actions; however, those goals do not go into effect
until fiscal year 2015. See Food & Drug Admin., GDUFA Program Performance Goals
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thereby allowing a company to earn a return on its investment
quicker than if it had chosen the ANDA suitability petition route.
A corollary to a company choosing to submit a section
505(b)(2) NDA to the FDA instead of availing itself of the
suitability petition route to ANDA submission and approval is that
approval of a section 505(b)(2) NDA may be used to “short circuit”
a generic drug sponsor’s plans to obtain approval of a petitioned
ANDA for the same change covered by an approved section
505(b)(2) NDA. First, the FDA will not approve a pending
suitability petition for a change that describes an approved
pharmaceutically equivalent drug product, because the suitability
petition process is intended for a proposed “drug product which is
not identical to a listed drug in route of administration, dosage
form, and strength, or in which one active ingredient is substituted
106
for one of the active ingredients in a listed combination drug.”
Second, the FDA has historically required a generic drug applicant
with a pending ANDA subject to an approved suitability petition to
change RLD and provide appropriate bioequivalence information
once the Agency has approved an application for the drug product
107
covered by the suitability petition. A change made to the statute
by the 2003 MMA, however, precludes the sponsor of a pending
108
ANDA from amending its application to change RLD. Instead,
the FDA requires the submission of a new ANDA citing the
appropriate RLD, containing sufficient information to demonstrate
bioequivalence to that RLD, and certifications to any patents listed
109
in the Orange Book for that RLD.
Finally, it should be noted that the FDA has limited resources,
but an increasing amount of responsibility. This likely requires the
FDA to choose which tasks and obligations should take precedence
over others. With respect to ANDAs, the FDA has seen a nearand Procedures, http://www.fda.gov/downloads/ForIndustry/UserFees/Generic
DrugUserFees/UCM282505.pdf (last visited Apr. 28, 2014).
106. 21 C.F.R. § 314.93(b) (2013).
107. See Letter from Janet Woodcock, Dir., Ctr. for Drug Evaluation Research,
to Mark S. Aikman, Vice President, Regulatory Affairs and Quality Assurance,
Osmotica Pharm. Corp. (Nov. 25, 2008) (quoting Letter from G. Buehler, Dir.,
Office of Generic Drugs, Food & Drug Admin., to Undisclosed Applicants
Regarding ANDAs for Carboplatin Injection, 10 mg/mL (Aug. 12, 2004)),
available at http://www.regulations.gov/#!documentDetail;D=FDA-2008-P-0329
-0016.
108. See FDC Act § 505(j)(2)(D)(i), 21 U.S.C. § 355(j)(2)(D)(i) (2012).
109. See Letter from Janet Woodcock, supra note 107.
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tripling of applications submitted to the Agency over the past
decade, resulting in a significant backlog of applications. The
“slippage” in reviewing and acting on suitability petitions and the
increase in ANDA submissions and the backlog of pending
110
applications are likely not coincidence.
V. REDEMPTION OF FAITH: THE FDA SHOULD IMPLEMENT
PROCEDURES TO CONSISTENTLY MEET THE NINETY-DAY
STATUTORY DEADLINE FOR ACTING ON ANDA SUITABILITY
PETITIONS, OR CONGRESS SHOULD AMEND THE LAW WITH A
MORE PRACTICAL DEADLINE
Despite the FDA’s historical policy of sloth and lassitude in
ruling on ANDA suitability petitions, leading to a loss of faith in the
process itself, there is still hope that the FDA can redeem itself. But
to do so, the FDA will need to make a concerted effort to promptly
act on ANDA suitability petitions. Indeed, such an effort is already
afoot at the FDA. In August 2013, the FDA published a Manual of
111
Policies and Procedures (MaPP) establishing the policies and
procedures for responding to suitability petitions, and reiterating
that “[u]nder 21 CFR 314.93(e), the Agency will approve or deny
112
the petition no later than 90 days after the petition is submitted.”
According to the MaPP:
OGD’s goal is to respond to suitability petitions in an
efficient and effective manner. To meet this goal, a
number of parties within the Center for Drug Evaluation
and Research (CDER) and throughout the Agency must
work in a coordinated manner. OGD, the office primarily
responsible for responding to suitability petitions, has
developed procedures for enhancing communication
among parties involved in addressing the request(s) in the
113
suitability petitions.
Because the FDA’s MaPP became effective only relatively recently,
in August 2013, it is not yet clear what effect (if any) it has had on
speeding up the FDA’s review of new and long-pending ANDA
suitability petitions. If, given the passage of time, the policies and
procedures stated in the MaPP do not yield significant
110. Indeed, the personnel in the FDA’s OGD tasked with reviewing ANDAs
are the same personnel tasked with handling suitability petitions.
111. CTR. FOR DRUG EVALUATION & RESEARCH, supra note 86.
112. Id. at 1.
113. Id. at 2.

Published by Mitchell Hamline Open Access, 2014

27

William Mitchell Law Review, Vol. 40, Iss. 4 [2014], Art. 3

2014]

ANDA SUITABILITY PETITIONS

1287

improvements in meeting the statutory ninety-day deadline, then
perhaps Congress should amend the statute to reset the deadline to
one that is more practical for the FDA to meet.
In other recent instances where Congress has required the
FDA to respond to certain types of citizen petitions in 150 days,
180 days, and 270 days, the FDA has been quite successful in
meeting those statutory deadlines. In 2007, the FDC Act was
amended to require that the FDA respond, within 180 days, to
certain citizen petitions and petitions for stays of action that
request that the FDA take any form of action related to a pending
114
ANDA or section 505(b)(2) NDA. That 180-day deadline was
115
reduced to 150 days in 2012. Of the 116 petitions submitted to
the FDA through fiscal year 2012 subject to the 180-day or 150-day
116
deadline, the FDA has missed that deadline only twice.
117
The FDC Act was also amended in 2012 to require that the
FDA respond within 270 days to citizen petitions requesting that
the FDA determine whether a particular RLD was withdrawn from
118
sale for reasons of safety or effectiveness. The FDA has thus far
114. See FDC Act § 505(q), 21 U.S.C. § 355(q) (2012). This section of the law
was added by section 914 of the Food and Drug Administration Amendments Act
of 2007, Pub. L. No. 110-85, § 914, 121 Stat. 823, 953–57.
115. See Food and Drug Administration Safety and Innovation Act, Pub. L.
No. 112-144, § 1135, 126 Stat. 993, 1123 (2012).
116. See FOOD & DRUG ADMIN., REPORT TO CONGRESS, FIFTH ANNUAL REPORT ON
DELAYS IN APPROVALS OF APPLICATIONS RELATED TO CITIZEN PETITIONS AND PETITIONS
FOR STAY OF AGENCY ACTION FOR FISCAL YEAR 2012, at 4 (2013), available at http://
www.fda.gov/downloads/AboutFDA/CentersOffices/OfficeofMedicalProductsand
Tobacco/CDER/ReportsBudgets/UCM369780.pdf; see also Kurt R. Karst, FDA’s
Fifth Annual Report to Congress on 505(q) Citizen Petitions: Something Old, Something
New, Something Borrowed, FDA Is Still Blue, FDA L. BLOG (Sept. 25, 2013),
http://www.fdalawblog.net/fda_law_blog_hyman_phelps/2013/09/fdas-fifth
-annual-report-to-congress-on-505q-citizen-petitions-something-old-something-new
-something.html.
117. See FDC Act § 505(w), 21 U.S.C. § 355(w). This section of the law was
added by section 1134 of the Food and Drug Administration Safety and Innovation
Act, Pub. L. No. 112-144, § 1134, 126 Stat. 993, 1123 (2012).
118. The FDA may refuse to approve an ANDA if the Agency determines that
the RLD was withdrawn from sale for reasons of safety or effectiveness. See FDC Act
§ 505(j)(4)(I), 21 U.S.C. § 355(j)(4)(I). In addition, the FDA can withdraw (or
suspend) approval of an ANDA if the RLD is withdrawn from sale for reasons of
safety or effectiveness. See FDC Act § 505(j)(6), 21 U.S.C. § 355(j)(6). The FDA
acknowledged in the preamble to the Agency’s July 1989 proposed regulations
implementing the 1984 Hatch-Waxman Act that the law does not “specify
procedures to be followed in determining whether a drug that is voluntarily
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met that deadline for the relatively small number of petitions
submitted pursuant to 21 C.F.R. § 314.161.
Clearly, the FDA can meet a statutory deadline for responding
to a citizen petition when the Agency wants to do so, and when the
Agency has sufficient time to do so. Perhaps the ninety-day
deadline for approving or disapproving an ANDA suitability
petition is insufficient for the FDA to complete its analysis and
compose a decision. There might also be a mindset at the FDA that
once the ninety-day period is breached, there is less impetus for the
FDA to promptly rule on a suitability petition. That is, there may be
a mindset that “a miss is a miss no matter how close to, or far off of,
the mark you are.” To address both of these issues, Congress
should consider extending––perhaps as part of the next iteration of
the Generic Drug User Fee Amendments of 2012 (GDUFA) that
will be taken up in the coming years––the ninety-day response
deadline to reflect deadlines that are more familiar to and
attainable by the FDA, such as the 150-day, 180-day, or 270-day
petition response deadlines imposed by Congress in recent years.
An attainable deadline will give greater certainty to the ANDA
suitability petition process, will reassure the generic drug industry
that it is a viable and practical route to ANDA approval, and may
lead to a renewed interest in submitting ANDA suitability
119
petitions.
withdrawn from sale by its manufacturer is withdrawn for safety or effectiveness
reasons.” Abbreviated New Drug Application Regulations, 54 Fed. Reg. 28,872,
28,907 (proposed July 10, 1989). As such, the FDA took it upon itself to create
such a procedure. The FDA’s interpretation of the Hatch-Waxman Act is
embodied in the Agency’s regulations, which provide that “[a]ny person may
petition under §§ 10.25(a) and 10.30 of this chapter for a determination whether
a listed drug has been voluntarily withdrawn for safety or effectiveness reasons.”
21 C.F.R. § 314.161(b) (2013).
119. There are alternatives to amending the FDC Act’s ANDA suitability
petition provisions with a more practical deadline. For example, Congress could
abolish the suitability petition procedures because the section 505(b)(2) NDA
pathway already provides a route to obtain approval of an application for the types
of changes permitted in a suitability petition, and without the need to first obtain
the FDA’s permission. Small generic drug companies that may use the suitability
petition procedures might object to such a move because of the significant user
fee payment that must accompany a section 505(b)(2) NDA submission (and
annual product and establishment user fee payments), unless PDUFA is also
amended to include a reduction or exemption from user fees. Congress could also
amend the FDC Act to permit the submission of an ANDA for a petitioned change
unless the FDA disapproves a petition within ninety days of submission. Such a
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VI. CONCLUSION
Despite initial popularity, interest in the ANDA suitability
petition has waned in recent years. This is likely the result of a
confluence of factors; however, the FDA’s inability to meet the
statutory ninety-day deadline for approving or disapproving a
suitability petition has resulted in a loss of faith in the petition
process. The petitioned ANDA remains a viable route for many
generic drug applicants to obtain approval of a drug product
without having to conduct expensive and time-consuming clinical
studies, but to renew trust and reinvigorate interest in the
petitioned ANDA, change is necessary. Recently, the FDA indicated
that it is committed to acting promptly on suitability petitions. If
the FDA’s renewed interest in meeting the statutory ninety-day
deadline is unsuccessful, then Congress should consider amending
the FDC Act with a more practical deadline.

change would effectively remove the condition precedent currently in the statute
and create greater urgency for FDA to review and act on a suitability petition in a
timely manner.
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APPENDIX
Table 1: ANDA Suitability Petition Submissions by Year
(1984–2013)
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Table 2: ANDA Suitability Petition Approvals by Year (1984–2013)
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Table 3: ANDA Suitability Petition Denials by Year (1984–2013)
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Table 4: ANDA Suitability Petition Withdrawals by Year
(1984–2013)
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Table 5: Pending ANDA Suitability Petitions by Year (2001–2013)
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Table 6: ANDA Suitability Petition Approvals, Denials,
Withdrawals, and Pending by Year (1984–2013)

Approved Suitability Petitions

80

Denied Suitability Petitions
70

Withdrawn Suitability Petitions
Pending Suitability Petitions
(as of 12/31/2013)

Number of Petitions

60
50
40
30
20
10

1984
1985
1986
1987
1988
1989
1990
1991
1992
1993
1994
1995
1996
1997
1998
1999
2000
2001
2002
2003
2004
2005
2006
2007
2008
2009
2010
2011
2012
2013

0

Year

Published by Mitchell Hamline Open Access, 2014

37

William Mitchell Law Review, Vol. 40, Iss. 4 [2014], Art. 3

2014]

ANDA SUITABILITY PETITIONS

1297

Table 7: Average Number of Days to FDA Decision (Approval or
Denial) by Year (1984–2013)—Excluding Pending Petitions
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Table 8: Median Number of Days to FDA Decision (Approval or
Denial) by Year (1984–2013)—Excluding Pending Petitions
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Table 9: Average and Median Number of Days to FDA Decision
(Approval or Denial) by Year (1984–2013)—
Excluding Pending Petitions
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Table 10: Average Number of Days to FDA Decision (Approval or
Denial) by Year (1984–2013)—Including Pending Petitions
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Table 11: Median Number of Days to FDA Decision (Approval or
Denial) by Year (1984–2013)—Including Pending Petitions
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Table 12: Average and Median Number of Days to FDA Decision
(Approval or Denial) by Year (1984–2013)—
Including Pending Petitions
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Table 13: ANDA Suitability Petition Submission & Action
by Year (1984–2013)––Excluding Pending Petitions
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Table 14: ANDA Suitability Petition Submission and Action by
Year (1984–2013) –– Including Pending Petitions
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Table 15: ANDA Suitability Petition Submissions by Year
(1984–2013)—Trend
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Table 16: Average & Median Number of Days to FDA
Decision (Approval or Denial) by Year (1984–2013)—
Excluding Pending Petitions—Trend
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